ICM
BCRX icon

ISZO Capital Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

ISZO Capital Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		$2.58M Buy
+307,366
New +$2.14M 4.49% 9

Other funds holding BCRX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ISZO Capital Management's BCRX Position: Q1 2017 in Review

ISZO Capital Management opened a new position in BioCryst Pharmaceuticals (BCRX) in Q1 2017: 307,366 shares worth $2.58M. The stake represents 4.49% of the portfolio and ranks #9 among its holdings.

117 funds tracked by Wall St. Rank hold BCRX as of Q1 2017.

  • ISZO Capital Management held 307,366 shares of BioCryst Pharmaceuticals worth $2.58M as of Q1 2017.
  • BioCryst Pharmaceuticals was a new ISZO Capital Management position in Q1 2017.
  • BioCryst Pharmaceuticals made up 4.49% of ISZO Capital Management's portfolio in Q1 2017, its #9 holding.
  • 117 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2017.

Based on ISZO Capital Management's 13F filing for Q1 2017, filed 15 May 2017.